The underlying cause of bladder cancer is found in DNA mutations, leading to abnormal protein expression. These mutations can cause malignant cell proliferation. Current diagnostic tests have poor sensitivity and focus on abnormal protein biomarker detection, which is downstream from the cause of the problem.
Convergent Genomics has developed UroAmplitude, a proprietary urine sequencing platform. UroAmplitude progresses beyond the biomarker era, going to the cause of malignancy – the DNA mutations. By sequencing 60 genes associated with urothelial cancer, this revolutionary technology evaluates over 240,000 locations where a mutation could exist, providing previously unachievable insight.
2021 Association of Medical Illustrators Conference Salon
”You guys are awesome and I'm super happy with the final product. Trevor LevinCo-founder and CEO at Convergent Genomics
”You guys are awesome and I'm super happy with the final product.
1275 Shiloh Road, Suite 3130 Kennesaw, GA 30144 | Toll-free: 800-333-0753 | Phone: 770-805-0460 | Email: Nucleus Medical Media
©2021 Nucleus Medical Media. All rights reserved.